Filing Flows › Health Care › Establishment Labs Holdings (ESTA)
Establishment Labs Holdings (ESTA) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · Establishment Labs Holdings (ESTA) Q3 2026 earnings results →
Q3 2026 Revenue up 34% year over year to $72.0M · 15¢ of every $1 of revenue lost · operating margin -3.6%
Establishment Labs Holdings made $72.0M in Q3 2026 (+34% Y/Y). Operating margin -3.6%, net loss $10.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $72.0M in Q3 2026, up 34% year over year and up 7% from the previous quarter.
Gross margin was 69.1%, down 1.0 points from Q3 2025. Operating costs exceeded revenue by $2.6M, an operating margin of -3.6%. Operating expenses grew 25% against revenue growth of 34%. The fastest-growing cost line was SG&A (+29%). The quarter ended with a net loss of $10.7M, narrower than the previous quarter's $11.7M loss. Net interest and other expense of $7.5M was the main reason.
Operating cash flow was $7.7M. Non-cash charges added back $2.9M of share-based compensation. Working capital and other items added $15.5M. After cost incurred for intangible assets ($1.7M) and purchases of property and equipment ($885K), free cash flow as the company reports it was $5.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 6, 2026 | $72.0M | +34% | -3.6% | −$10.7M | $7.7M |
| Q2 2026 | 10-Q | Aug 7, 2026 | $67.5M | +32% | -6.4% | −$11.7M | −$16.6M |
| Q1 2026 | 10-Q | May 8, 2026 | $59.9M | +45% | -10.9% | −$13.4M | −$4.3M |
| Q4 2025 | 10-K | Feb 27, 2026 | $64.6M | +45% | -6.1% | −$2.6M | −$162K |
| Q3 2025 | 10-Q | Nov 7, 2025 | $53.8M | +34% | -7.5% | −$11.1M | −$11.2M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $51.3M | +16% | -27.5% | −$16.6M | −$18.8M |
| Q1 2025 | 10-Q | May 9, 2025 | $41.4M | +11% | -41.0% | −$20.7M | −$20.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Establishment Labs Holdings
We are a global medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market. We initially incorporated in Costa Rica in 2004 and subsequently reorganized in 2013 under a parent holding company in the British Virgin Islands. Our line of silicone gel-filled breast implants, branded as Motiva Implants, is the centerpiece of our medical technology platform. Our 5-year results from our Motiva U.S. IDE study as well as our patient and practitioner reported post-market surveillance data indicate that Motiva Implants have low rates of adverse events (including rupture, capsular contracture, and implant-related reoperations) that compare favorably with those of our competitors.
In its own words, from its 10-K, filed Feb 27, 2026.
Establishment Labs Holdings against its Orthopedic, Prosthetic & Surgical Appliances & Supplies peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +34% against the peers' median +10%. Operating margin: -3.6% against the peers' median 16.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ESTA Establishment Labs Holdings | Q3 2026 | $72.0M | +34% | -3.6% |
| ISRG Intuitive Surgical | Q3 2026 | $3.0B | +22% | 19.4% |
| ZBH Zimmer Biomet Holdings | Q3 2026 | $2.1B | +3% | 14.9% |
| EW Edwards Lifesciences | Q3 2026 | $1.7B | +10% | 17.4% |
| STE Steris | Q2 FY27 | $1.6B | +9% | 18.5% |
| ALGN Align Technology | Q3 2026 | $1.0B | +2% | 16.7% |
| ENOV Enovis | Q3 2026 | $559M | +2% | 0.6% |
| MSA MSA Safety | Q3 2026 | $536M | +14% | 16.4% |
| CDRE Cadre Holdings | Q3 2026 | $203M | +30% | 14.0% |
Source: Establishment Labs Holdings 10-Q on SEC EDGAR · CIK 1688757 · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Guidance and outlook
More on ESTA
- How Establishment Labs Holdings makes money: revenue by segment
- Establishment Labs Holdings next earnings date and what analysts expect
- Establishment Labs Holdings stock forecast, price target and fair value
- Establishment Labs Holdings guidance and outlook
- Establishment Labs Holdings recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results